<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:00:15Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8607926" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8607926</identifier>
        <datestamp>2021-11-23</datestamp>
        <setSpec>erjopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Eur Respir J</journal-id>
              <journal-id journal-id-type="iso-abbrev">Eur Respir J</journal-id>
              <journal-id journal-id-type="publisher-id">ERJ</journal-id>
              <journal-id journal-id-type="hwp">erj</journal-id>
              <journal-title-group>
                <journal-title>The European Respiratory Journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0903-1936</issn>
              <issn pub-type="epub">1399-3003</issn>
              <publisher>
                <publisher-name>European Respiratory Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8607926</article-id>
              <article-id pub-id-type="pmcid">PMC8607926</article-id>
              <article-id pub-id-type="pmc-uid">8607926</article-id>
              <article-id pub-id-type="pmid">33986030</article-id>
              <article-id pub-id-type="pmid">33986030</article-id>
              <article-id pub-id-type="doi">10.1183/13993003.04240-2020</article-id>
              <article-id pub-id-type="publisher-id">ERJ-04240-2020</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="VoR">Version of Record</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research Articles</subject>
                  <subj-group>
                    <subject>Cough</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>18</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study</article-title>
                <alt-title alt-title-type="short">Eliapixant in refractory chronic cough</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6135-9610</contrib-id>
                  <name>
                    <surname>Morice</surname>
                    <given-names>Alyn</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8837-4928</contrib-id>
                  <name>
                    <surname>Smith</surname>
                    <given-names>Jaclyn A.</given-names>
                  </name>
                  <xref rid="af2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McGarvey</surname>
                    <given-names>Lorcan</given-names>
                  </name>
                  <xref rid="af3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Birring</surname>
                    <given-names>Surinder S.</given-names>
                  </name>
                  <xref rid="af4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Parker</surname>
                    <given-names>Sean M.</given-names>
                  </name>
                  <xref rid="af5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Turner</surname>
                    <given-names>Alice</given-names>
                  </name>
                  <xref rid="af6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9713-0183</contrib-id>
                  <name>
                    <surname>Hummel</surname>
                    <given-names>Thomas</given-names>
                  </name>
                  <xref rid="af7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gashaw</surname>
                    <given-names>Isabella</given-names>
                  </name>
                  <xref rid="af8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fels</surname>
                    <given-names>Lueder</given-names>
                  </name>
                  <xref rid="af8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Klein</surname>
                    <given-names>Stefan</given-names>
                  </name>
                  <xref rid="af8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Francke</surname>
                    <given-names>Klaus</given-names>
                  </name>
                  <xref rid="af8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Friedrich</surname>
                    <given-names>Christian</given-names>
                  </name>
                  <xref rid="af8" ref-type="aff">8</xref>
                </contrib>
              </contrib-group>
              <aff id="af1"><label>1</label>Respiratory Research Group, Hull York Medical School, University of Hull, Hull, UK</aff>
              <aff id="af2"><label>2</label>Manchester University NHS Foundation Trust and Manchester Academic Health Science Centre, Manchester, UK</aff>
              <aff id="af3"><label>3</label>Wellcome Wolfson Institute of Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK</aff>
              <aff id="af4"><label>4</label>Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College Hospital, London, UK</aff>
              <aff id="af5"><label>5</label>North Tyneside Hospital, Northumbria Healthcare NHS Foundation Trust, North Shields, UK</aff>
              <aff id="af6"><label>6</label>Institute of Applied Health Research and Population Sciences, University of Birmingham, Birmingham, UK</aff>
              <aff id="af7"><label>7</label>Smell and Taste Clinic, Dept of Otorhinolaryngology, TU Dresden, Dresden, Germany</aff>
              <aff id="af8"><label>8</label>Bayer AG, Berlin, Germany</aff>
              <author-notes>
                <corresp id="cor1">Corresponding author: Alyn Morice (<email xlink:href="a.h.morice@hull.ac.uk">a.h.morice@hull.ac.uk</email>)</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <volume>58</volume>
              <issue>5</issue>
              <elocation-id>2004240</elocation-id>
              <history>
                <date date-type="received">
                  <day>17</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>05</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright Â©The authors 2021.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact <ext-link ext-link-type="uri" xlink:href="mailto:permissions@ersnet.org">permissions@ersnet.org</ext-link></license-p>
                </license>
              </permissions>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>ATP acting <italic toggle="yes">via</italic> P2X3 receptors is an important mediator of refractory chronic cough (RCC). This phase 2a double-blinded crossover study assessed the safety, tolerability and efficacy of eliapixant (BAY 1817080), a selective P2X3 receptor antagonist, in adults with RCC attending specialist centres.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>In period A, patients received placebo for 2âweeks then eliapixant 10âmg for 1âweek. In period B, patients received eliapixant 50, 200 and 750âmg twice daily for 1âweek per dose level. Patients were randomised 1:1 to period AâB (n=20) or BâA (n=20). The primary efficacy end-point was change in cough frequency assessed over 24âh. The primary safety end-point was frequency and severity of adverse events (AEs).</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>37 patients completed randomised therapy. Mean cough frequency fell by 17.4% <italic toggle="yes">versus</italic> baseline with placebo. Eliapixant reduced cough frequency at doses â¥50âmg (reduction <italic toggle="yes">versus</italic> placebo at 750âmg: 25% (90% CI 11.5â36.5%); p=0.002). Doses â¥50âmg also significantly reduced cough severity. AEs, mostly mild or moderate, were reported in 65% of patients with placebo and 41â49% receiving eliapixant. Cumulative rates of taste-related AEs were 3% with placebo and 5â21% with eliapixant; all were mild.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>Selective P2X3 antagonism with eliapixant significantly reduced cough frequency and severity, confirming this as a viable therapeutic pathway for RCC. Taste-related side-effects were lower at therapeutic doses than with the less selective P2X3 antagonist gefapixant. Selective P2X3 antagonism appears to be a novel therapeutic approach for RCC.</p>
                </sec>
              </abstract>
              <abstract abstract-type="short">
                <p>
                  <bold>The highly selective P2X3 antagonist eliapixant (BAY 1817080) significantly reduced cough frequency and severity in patients with refractory chronic cough. Mild taste-related adverse events were reported in 5â21% of patients, depending on the dose.</bold>
                  <ext-link xlink:href="https://bit.ly/3afVlVM" ext-link-type="uri">https://bit.ly/3afVlVM</ext-link>
                </p>
              </abstract>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Bayer</institution>
                      <institution-id institution-id-type="doi">10.13039/100004326</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Chronic cough is generally defined as a cough lasting for â¥8âweeks [<xref rid="C1" ref-type="bibr">1</xref>, <xref rid="C2" ref-type="bibr">2</xref>] and is estimated to affect â¼10% of all adults [<xref rid="C3" ref-type="bibr">3</xref>, <xref rid="C4" ref-type="bibr">4</xref>]. Cough that persists despite standard therapy for potential underlying treatable traits is known as refractory chronic cough (RCC). In some cases, no clear underlying pathology is elicited (unexplained chronic cough (UCC)). The same empirical treatment regimen is often applied for UCC or RCC and therefore, for simplicity, both groups are referred to here as RCC. RCC has substantial effects on physical and psychological quality of life [<xref rid="C5" ref-type="bibr">5</xref>, <xref rid="C6" ref-type="bibr">6</xref>], including stress urinary incontinence, interference with speech and depression. There is a lack of licensed treatments for RCC, and off-label treatments such as opiates, tricyclic antidepressants, pregabalin and gabapentin have limited efficacy and can be associated with adverse effects [<xref rid="C7" ref-type="bibr">7</xref>].</p>
              <p>Dysregulation of neuronal pathways of the cough reflex is an underlying pathophysiology in RCC [<xref rid="C8" ref-type="bibr">8</xref>, <xref rid="C9" ref-type="bibr">9</xref>]. Recent evidence suggests that ATP activating purinergic P2X3 receptors is an important mediator in RCC [<xref rid="C10" ref-type="bibr">10</xref>â<xref rid="C14" ref-type="bibr">14</xref>]. P2X receptors consist of three transmembrane protein subunits forming an ion channel [<xref rid="C15" ref-type="bibr">15</xref>â<xref rid="C18" ref-type="bibr">18</xref>]. Seven subunits, numbered P2X1 to P2X7, have been identified. P2X3 receptors occur as homotrimers (<italic toggle="yes">e.g.</italic> with three P2X3 subunits, termed a P2X3 receptor) or heterotrimers (<italic toggle="yes">e.g.</italic> with two P2X3 subunits and one P2X2 subunit, termed a P2X2/3 receptor) [<xref rid="C15" ref-type="bibr">15</xref>â<xref rid="C18" ref-type="bibr">18</xref>]. P2X3 receptors are predominantly expressed on small-to-medium diameter afferent vagal C or AÎ´ fibres. Activation of these fibres by P2X3 receptor-dependent ATP signalling has been demonstrated in cell culture and <italic toggle="yes">in vivo</italic> models [<xref rid="C8" ref-type="bibr">8</xref>, <xref rid="C19" ref-type="bibr">19</xref>].</p>
              <p>A change in the cough reflex from physiological (defensive) to excessive pathological (hypersensitivity) involves both peripheral and central neuronal adaption. This enhanced responsiveness reflects functional changes in nerves and signalling receptors, including P2X3, and consequent upregulation of sensory neuronal activity [<xref rid="C9" ref-type="bibr">9</xref>, <xref rid="C20" ref-type="bibr">20</xref>â<xref rid="C23" ref-type="bibr">23</xref>]. The role of P2X3 receptors in the pathophysiology of chronic cough is well supported by trials of the P2X3 and P2X2/3 receptor antagonist gefapixant (AF-219; MK7264) [<xref rid="C10" ref-type="bibr">10</xref>, <xref rid="C13" ref-type="bibr">13</xref>, <xref rid="C20" ref-type="bibr">20</xref>, <xref rid="C23" ref-type="bibr">23</xref>, <xref rid="C24" ref-type="bibr">24</xref>]. Use of gefapixant has been limited to some extent by significant dysgeusia, attributed to action on the P2X2/3 receptor [<xref rid="C13" ref-type="bibr">13</xref>, <xref rid="C14" ref-type="bibr">14</xref>, <xref rid="C23" ref-type="bibr">23</xref>, <xref rid="C24" ref-type="bibr">24</xref>]. If the benefits on cough are mainly mediated by the P2X3 component, which is currently unknown, highly selective P2X3 receptor antagonists may represent a promising novel class of antitussives with potential for fewer side-effects [<xref rid="C8" ref-type="bibr">8</xref>, <xref rid="C18" ref-type="bibr">18</xref>]. <italic toggle="yes">In vitro</italic> studies of eliapixant (BAY 1817080), a novel P2X3 receptor antagonist, showed that it has high selectivity for P2X3 receptors over P2X2/3 receptors (Bayer, data on file). Eliapixant is well tolerated in healthy volunteers after single and multiple dosing, and is under investigation in multiple indications involving nerve hypersensitisation (Bayer, data on file). Here we report a phase 2a study of eliapixant in RCC.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods</title>
              <sec id="s2a">
                <title>Study overview and design</title>
                <p>This was a two-part, double-blinded, placebo-controlled, randomised, parallel-group study (<ext-link xlink:href="https://clinicaltrials.gov/" ext-link-type="uri">ClinicalTrials.gov</ext-link>: NCT03310645). Part 1, a phase 1 multiple dose escalation study in healthy volunteers investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of doses of eliapixant between 10 and 750âmg over 14âdays, will be reported elsewhere. Part 2, reported here, was a two-way crossover phase 2a study of four different doses of eliapixant in patients with RCC, conducted between 29 June 2018 (first informed consent) and 28 May 2019 (last visit), following finalisation of part 1.</p>
                <p>The protocol for this study is not publicly available, but redacted information is available on request.</p>
              </sec>
              <sec id="s2b">
                <title>Participants</title>
                <p>Patients were recruited from six UK centres by investigators experienced in the management of chronic cough. Eligible patients were aged &gt;18âyears, with body mass index (BMI) 18â35âkgÂ·m<sup>â2</sup>, diagnosed with RCC for â¥1âyear, unresponsive to treatment according to the 2006 British Thoracic Society guidelines [<xref rid="C25" ref-type="bibr">25</xref>] and a score &gt;40âmm on the cough severity visual analogue scale (VAS) at screening. To accelerate recruitment, patients previously treated with P2X3 receptor antagonists were eligible as long as any prior investigational drug was received at least 2âmonths (or â¼5 half-lives of the drug if &gt;2âmonths) before the first dose of study drug in the present study. Patients with forced expiratory volume in 1âs or forced vital capacity &lt;60% of predicted normal at screening were excluded. Patients were also excluded if they had received any systemic or topically active drug that modulates cough within 14âdays before first study drug administration or during the trial until the follow-up examination. Full inclusion and exclusion criteria are shown in <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary table S1</ext-link>.</p>
              </sec>
              <sec id="s2c">
                <title>Procedures</title>
                <p>Two treatment periods were employed. In period A, patients received placebo for 2âweeks followed by eliapixant 10âmg for 1âweek. In period B, patients received eliapixant in escalating doses of 50, 200 and 750âmg for 1âweek per dose level. Patients were randomised 1:1 to period A crossing over to B or <italic toggle="yes">vice versa</italic>, with a 3â4-week washout period between sequences (<xref rid="F1" ref-type="fig">figure 1</xref>). Inclusion of the 10âmg eliapixant dosage in period A allowed four dosages to be evaluated while reducing the study duration and the burden on participants. As a treatment time of 1âweek for each dosage of eliapixant had been chosen, a 2-week placebo period was necessary to give an equal duration (3âweeks) for periods A and B.</p>
                <fig position="float" id="F1">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Study design.</p>
                  </caption>
                  <graphic xlink:href="ERJ-04240-2020.01" position="float"/>
                </fig>
                <p>Eliapixant, as 10, 25 or 150âmg coated tablets, was administered twice daily under fed conditions, except for day 1 of each period when the dose was given three times to shorten time to steady state. Study visits took place at baseline and on the last day of each treatment week (days 6, 13 and 20); patients were therefore assessed at the end of week 1 and week 2 of placebo treatment. Cough monitoring and assessment of blood pressure and ECG took place at each visit. Adverse events (AEs) were monitored throughout the study. Taste-related AEs were assessed at first occurrence (as standard for crossover studies), and in a cumulative assessment in which events that started at one dose level and persisted into the next were counted again at each dose for which they were present. Taste-related AEs included hypogeusia (quantitative reduction in taste sensation), ageusia (complete loss of sense of taste), parageusia (changed qualitative perception of taste qualities) and dysgeusia (any alteration in taste not otherwise specified) [<xref rid="C26" ref-type="bibr">26</xref>].</p>
              </sec>
              <sec id="s2d">
                <title>Outcomes</title>
                <p>The primary efficacy end-point was the change in cough frequency per hour, assessed objectively over 24-h periods using a cough recorder (VitaloJAK; Vitalograph, Maids Moreton, UK) [<xref rid="C27" ref-type="bibr">27</xref>, <xref rid="C28" ref-type="bibr">28</xref>]. In each study period, cough frequency was assessed pre-dose (day 1) and at the end of each treatment week (days 7, 14 and 21). Hourly cough frequencies while awake and asleep were also assessed. Other key efficacy end-points were patient-reported cough severity and cough-related quality of life, assessed by 100-mm VAS and Leicester Cough Questionnaire (LCQ), respectively. The primary safety end-point was the frequency and severity of AEs. Pharmacokinetic analyses were performed by validated chromatographic methods using a sparse sampling protocol on blood samples taken at 2, 4 and 6âh post-dose on day 0, and at 0, 2, 4, 6 and 23.5âh post-dose on days 6, 13 and 20.</p>
              </sec>
              <sec id="s2e">
                <title>Study oversight and approvals</title>
                <p>The protocol and all amendments were reviewed and approved by the West London and GTAC (Gene Therapy Advisory Committee) Research Ethics Committee of the Health Research Authority (17/LO/1103) before the start of the study. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonisation guideline on Good Clinical Practice. All patients were informed about the observed safety and tolerability profile from phase 1, were warned about the possibility of taste-related AEs based on published experience with gefapixant and provided written informed consent.</p>
              </sec>
              <sec id="s2f">
                <title>Randomisation, blinding and statistical techniques</title>
                <p>Since the study was a proof-of-concept study, a Bayesian approach with noninformative prior distributions was used for statistical analysis. Results were reported presenting 90% credible limits, which are equivalent to frequentist analyses with 90% confidence intervals. For the (Bayesian) ANCOVA on the primary end-points, two different baselines were used for each patient: the first baseline before period A and the second baseline before period B. This approach was chosen due to the crossover design, because it allows adjustment for unequal carryover effects. Changes from baseline and changes <italic toggle="yes">versus</italic> placebo were determined from paired data using suitable contrasts. Percentages were rounded to the nearest integer and totals may therefore not sum to 100%. Randomisation, blinding and statistical techniques are described further in the <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary material</ext-link>.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <sec id="s3a">
                <title>Patient characteristics and disposition</title>
                <p>In total, 61 patients were enrolled. After exclusion of 21 screening failures, 40 were randomised: 20 to treatment sequence AâB and 20 to treatment sequence BâA (<xref rid="F2" ref-type="fig">figure 2</xref>). The study was completed according to protocol. Two patients (5%) discontinued study drug because of AEs (see Safety section) and one patient withdrew for personal reasons. In total, therefore, 37 patients completed randomised treatment. All 40 patients completed follow-up and were included in the safety set, and were also eligible for efficacy and pharmacokinetic evaluations (per-protocol set). During the study, 37 patients (93%) received concomitant medication, most commonly paracetamol (as a single drug in 17 patients (43%)). Indications for paracetamol included AEs such as headache (nine patients (23%)) and concomitant disease such as arthritis. Baseline characteristics were similar between the sequence groups (<xref rid="TB1" ref-type="table">table 1</xref>).</p>
                <fig position="float" id="F2">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Patient disposition. <sup>#</sup>: investigator assessment.</p>
                  </caption>
                  <graphic xlink:href="ERJ-04240-2020.02" position="float"/>
                </fig>
                <table-wrap position="float" id="TB1">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Baseline characteristics of patients (safety population)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Sequence AâB</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Sequence BâA</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Total</bold>
                        </td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Patients</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">20</td>
                        <td align="center" rowspan="1" colspan="1">20</td>
                        <td align="center" rowspan="1" colspan="1">40</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Sex</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âMale</td>
                        <td align="center" rowspan="1" colspan="1">6 (30)</td>
                        <td align="center" rowspan="1" colspan="1">3 (15)</td>
                        <td align="center" rowspan="1" colspan="1">9 (23)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âFemale</td>
                        <td align="center" rowspan="1" colspan="1">14 (70)</td>
                        <td align="center" rowspan="1" colspan="1">17 (85)</td>
                        <td align="center" rowspan="1" colspan="1">31 (78)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Race</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âBlack or African American</td>
                        <td align="center" rowspan="1" colspan="1">1 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âWhite</td>
                        <td align="center" rowspan="1" colspan="1">19 (95)</td>
                        <td align="center" rowspan="1" colspan="1">20 (100)</td>
                        <td align="center" rowspan="1" colspan="1">39 (98)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Age years</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">60.6Â±13.2</td>
                        <td align="center" rowspan="1" colspan="1">62.4Â±7.0</td>
                        <td align="center" rowspan="1" colspan="1">61.5Â±10.5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âRange</td>
                        <td align="center" rowspan="1" colspan="1">20â76</td>
                        <td align="center" rowspan="1" colspan="1">50â75</td>
                        <td align="center" rowspan="1" colspan="1">20â76</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>BMI kgÂ·m<sup>â2</sup></bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">26.7Â±3.1</td>
                        <td align="center" rowspan="1" colspan="1">26.9Â±3.7</td>
                        <td align="center" rowspan="1" colspan="1">26.8Â±3.4</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Smoking history</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âNever-smoker</td>
                        <td align="center" rowspan="1" colspan="1">14 (70)</td>
                        <td align="center" rowspan="1" colspan="1">11 (55)</td>
                        <td align="center" rowspan="1" colspan="1">25 (63)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âEx-smoker</td>
                        <td align="center" rowspan="1" colspan="1">6 (30)</td>
                        <td align="center" rowspan="1" colspan="1">9 (45)</td>
                        <td align="center" rowspan="1" colspan="1">15 (38)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Prior medication</bold>
                          <bold>
                            <sup>#</sup>
                          </bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">17 (85)</td>
                        <td align="center" rowspan="1" colspan="1">15 (75)</td>
                        <td align="center" rowspan="1" colspan="1">32 (80)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Geometric mean cough frequency h<sup>â1</sup> (90% CL)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">â24-h</td>
                        <td align="center" rowspan="1" colspan="1">25.4 (17.9â36.0)</td>
                        <td align="center" rowspan="1" colspan="1">24.6 (17.3â34.9)</td>
                        <td align="center" rowspan="1" colspan="1">24.9 (19.5â32.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âAwake</td>
                        <td align="center" rowspan="1" colspan="1">33.7 (23.6â48.1)</td>
                        <td align="center" rowspan="1" colspan="1">32.1 (22.5â45.9)</td>
                        <td align="center" rowspan="1" colspan="1">32.9 (25.6â42.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âAsleep</td>
                        <td align="center" rowspan="1" colspan="1">1.8 (1.1â2.8)</td>
                        <td align="center" rowspan="1" colspan="1">2.0 (1.3â3.3)</td>
                        <td align="center" rowspan="1" colspan="1">1.9 (1.3â2.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Cough severity VAS mm (90% CL)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">72.2 (64.9â79.6)</td>
                        <td align="center" rowspan="1" colspan="1">70.6 (63.3â78.0)</td>
                        <td align="center" rowspan="1" colspan="1">71.4 (66.2â76.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>LCQ total score (90% CL)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">11.2 (9.9â12.5)</td>
                        <td align="center" rowspan="1" colspan="1">10.7 (9.5â12.0)</td>
                        <td align="center" rowspan="1" colspan="1">11.0 (10.0â11.9)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Data are presented as n, n (%) or meanÂ±<sc>sd</sc>, unless otherwise stated. BMI: body mass index; CL: credible limit; VAS: visual analogue scale; LCQ: Leicester Cough Questionnaire. <sup>#</sup>: any prior medication used within 4âweeks before the screening visit.</p>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s3b">
                <title>Efficacy</title>
                <p>Cough frequency (measured over 24âh) decreased by a mean of 17.4% <italic toggle="yes">versus</italic> baseline with placebo and by 9.4â38.1% <italic toggle="yes">versus</italic> baseline with eliapixant (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary tables S2 and S3</ext-link>, and <xref rid="F3" ref-type="fig">figure 3a</xref>). Placebo-corrected changes with eliapixant ranged from +9.5% to â25.0% (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary tables S2 and S3</ext-link>, and <xref rid="F3" ref-type="fig">figure 3b</xref>). Awake cough frequency decreased by a mean of 13.9% <italic toggle="yes">versus</italic> baseline with placebo and by up to 36.4% <italic toggle="yes">versus</italic> baseline with eliapixant in a dose-related manner (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary tables S2 and S3</ext-link>, and <xref rid="F3" ref-type="fig">figure 3c</xref>). Placebo-corrected changes in awake cough frequency with eliapixant ranged from +5.2% to â26.1% (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary tables S2 and S3</ext-link>, and <xref rid="F3" ref-type="fig">figure 3d</xref>). No relevant period effects were observed, but pronounced sequence-by-period interactions were observed. However, both types of effects were accounted for in the statistical model by using different baselines for each period. Geometric mean cough frequencies are shown in <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S1</ext-link>.</p>
                <fig position="float" id="F3">
                  <label>FIGURE 3</label>
                  <caption>
                    <p>Mean changes in a, b) 24-h cough frequency and c, d) awake cough frequency <italic toggle="yes">versus</italic> a, c) baseline and b, d) placebo. Bayesian mixed model analysis (n=40); vertical bars represent 90% credible limits. Treatment time with each dose of eliapixant was 1âweek. <sc>ns</sc>: nonsignificant.</p>
                  </caption>
                  <graphic xlink:href="ERJ-04240-2020.03" position="float"/>
                </fig>
                <p>In a <italic toggle="yes">post hoc</italic> analysis the placebo adjustment as performed for trials of other P2X3 receptor antagonists [<xref rid="C29" ref-type="bibr">29</xref>], in which arithmetic rather than geometric means appear to have been used, was applied. In this analysis, cough frequency over 24âh and awake cough frequency were reduced by 30.6% and 32.1% <italic toggle="yes">versus</italic> placebo, respectively, with the 750âmg dose (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S2</ext-link>).</p>
                <p>Cough severity showed a dose-dependent reduction with eliapixant (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary tables S4 and S5</ext-link>, and <xref rid="F4" ref-type="fig">figure 4</xref>). Absolute cough severities are shown in <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S3</ext-link>.</p>
                <fig position="float" id="F4">
                  <label>FIGURE 4</label>
                  <caption>
                    <p>Mean changes in patient-reported cough severity (visual analogue scale) <italic toggle="yes">versus</italic> a) baseline and b) placebo. Point estimates; vertical lines represent 90% credible limits. One-sided p-values are shown. Treatment time with each dose of eliapixant was 1âweek. <sc>ns</sc>: nonsignificant.</p>
                  </caption>
                  <graphic xlink:href="ERJ-04240-2020.04" position="float"/>
                </fig>
                <p>Doses of eliapixant â¥50âmg increased the LCQ score (representing improvement) <italic toggle="yes">versus</italic> baseline and <italic toggle="yes">versus</italic> placebo (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary tables S6 and S7</ext-link>, and <xref rid="F5" ref-type="fig">figure 5</xref>).</p>
                <fig position="float" id="F5">
                  <label>FIGURE 5</label>
                  <caption>
                    <p>Mean changes in Leicester Cough Questionnaire (LCQ) total score <italic toggle="yes">versus</italic> a) baseline and b) placebo. Point estimates; vertical lines represent 90% credible limits. One-sided p-values are shown. Treatment time with each dose of eliapixant was 1âweek. <sc>ns</sc>: nonsignificant.</p>
                  </caption>
                  <graphic xlink:href="ERJ-04240-2020.05" position="float"/>
                </fig>
                <p>During the treatment phases, no patient took gabapentin, amitriptyline, opioids or any other drugs shown to affect RCC.</p>
              </sec>
              <sec id="s3c">
                <title>Safety</title>
                <p>AEs were reported in 65% of patients with placebo and 41â49% of patients receiving eliapixant, with no dose relationship (<xref rid="TB2" ref-type="table">table 2</xref>). Most AEs were mild or moderate in severity. AEs considered study drug related by the investigator were reported in 13% of patients with placebo and 0â21% of patients receiving eliapixant, with no dose relationship (<xref rid="TB2" ref-type="table">table 2</xref>). The most common study drug-related AEs overall were dysgeusia (n=9 (23%)) and headache (n=4 (10%)) (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary table S8</ext-link>). Two patients discontinued study drug because of AEs: one with vomiting of moderate intensity while receiving eliapixant 200âmg and one with moderate increases in liver enzymes while receiving placebo. The latter patient was subsequently diagnosed with pancreatitis due to a stone in the common bile duct. This was the only serious and severe AE reported during the study. Neither event leading to discontinuation was considered related to study drug by the investigator. No deaths occurred during the study. No clinically relevant changes in laboratory parameters or vital signs other than those mentioned were reported (data not shown).</p>
                <table-wrap position="float" id="TB2">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Summary of safety</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <td rowspan="2" align="left" colspan="1"/>
                        <td rowspan="2" align="center" colspan="1">
                          <bold>Placebo</bold>
                        </td>
                        <td colspan="4" align="center" rowspan="1">
                          <bold>Eliapixant</bold>
                        </td>
                        <td rowspan="2" align="center" colspan="1">
                          <bold>All treatments</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>10âmg</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>50âmg</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>200âmg</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>750âmg</bold>
                        </td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Patients</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">40</td>
                        <td align="center" rowspan="1" colspan="1">39</td>
                        <td align="center" rowspan="1" colspan="1">39</td>
                        <td align="center" rowspan="1" colspan="1">39</td>
                        <td align="center" rowspan="1" colspan="1">39</td>
                        <td align="center" rowspan="1" colspan="1">40</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Any AE</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">26 (65)</td>
                        <td align="center" rowspan="1" colspan="1">17 (44)</td>
                        <td align="center" rowspan="1" colspan="1">19 (49)</td>
                        <td align="center" rowspan="1" colspan="1">18 (46)</td>
                        <td align="center" rowspan="1" colspan="1">16 (41)</td>
                        <td align="center" rowspan="1" colspan="1">37 (93)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Severity of AE</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âMild</td>
                        <td align="center" rowspan="1" colspan="1">23 (58)</td>
                        <td align="center" rowspan="1" colspan="1">15 (38)</td>
                        <td align="center" rowspan="1" colspan="1">17 (44)</td>
                        <td align="center" rowspan="1" colspan="1">16 (41)</td>
                        <td align="center" rowspan="1" colspan="1">13 (33)</td>
                        <td align="center" rowspan="1" colspan="1">30 (75)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âModerate</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                        <td align="center" rowspan="1" colspan="1">6 (15)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âSevere</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Any study drug-related AE</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">5 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">8 (21)</td>
                        <td align="center" rowspan="1" colspan="1">8 (21)</td>
                        <td align="center" rowspan="1" colspan="1">5 (13)</td>
                        <td align="center" rowspan="1" colspan="1">14 (35)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Severity of study drug-related AE</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âMild</td>
                        <td align="center" rowspan="1" colspan="1">5 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">7 (18)</td>
                        <td align="center" rowspan="1" colspan="1">8 (21)</td>
                        <td align="center" rowspan="1" colspan="1">5 (13)</td>
                        <td align="center" rowspan="1" colspan="1">13 (33)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âModerate</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Any AE leading to discontinuation of study drug</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Any SAE</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Data are presented as n or n (%). AE: adverse event; SAE: serious adverse event.</p>
                  </table-wrap-foot>
                </table-wrap>
                <p>The most frequently reported AEs overall were headache, dysgeusia, fatigue and diarrhoea (<xref rid="TB3" ref-type="table">table 3</xref>). Dysgeusia, in terms of the first occurrence of the event, was reported in 8â10% of patients receiving eliapixant, with no dose relationship, and 3% of patients receiving placebo (<xref rid="TB3" ref-type="table">table 3</xref>). All taste-related AEs were mild in severity. There was no relationship between taste-related AEs and the magnitude of cough frequency reduction (data not shown). All taste-related AEs were reversible: their duration was &lt;30âdays in nine patients, 41âdays in one patient (dysgeusia) and 72âdays in one patient (dysgeusia).</p>
                <table-wrap position="float" id="TB3">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Adverse events (AEs) reported in â¥5% of patients in any group and taste-related AEs</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <td rowspan="2" align="left" colspan="1"/>
                        <td rowspan="2" align="center" colspan="1">
                          <bold>Placebo</bold>
                        </td>
                        <td colspan="4" align="center" rowspan="1">
                          <bold>Eliapixant</bold>
                        </td>
                        <td rowspan="2" align="center" colspan="1">
                          <bold>All treatments<sup>#</sup></bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>10âmg</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>50âmg</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>200âmg</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>750âmg</bold>
                        </td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Patients</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">40</td>
                        <td align="center" rowspan="1" colspan="1">39</td>
                        <td align="center" rowspan="1" colspan="1">39</td>
                        <td align="center" rowspan="1" colspan="1">39</td>
                        <td align="center" rowspan="1" colspan="1">39</td>
                        <td align="center" rowspan="1" colspan="1">40</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>AEs reported in â¥5% of patients in any group</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âHeadache</td>
                        <td align="center" rowspan="1" colspan="1">6 (15)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">5 (13)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">15 (38)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDysgeusia</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">4 (10)</td>
                        <td align="center" rowspan="1" colspan="1">4 (10)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                        <td align="center" rowspan="1" colspan="1">9 (23)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âFatigue</td>
                        <td align="center" rowspan="1" colspan="1">4 (10)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">8 (20)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDiarrhoea</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">7 (18)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âNasopharyngitis</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (15)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âUpper respiratory tract infection</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (13)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âCough</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (13)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDizziness</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (13)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âNausea</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">4 (10)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âOropharyngeal pain</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">4 (10)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDecreased appetite</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âNasal congestion</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDry throat</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âINR increased</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âLethargy</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âMyalgia</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âMacular rash</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âRhinorrhoea</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âAbdominal discomfort</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âLower abdominal pain</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âUpper abdominal pain</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDry mouth</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDyspepsia</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âOral paraesthesia</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âVomiting</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âFeeling cold</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âOral herpes</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âUrinary tract infection</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âFall</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Taste-related AEs<sup>Â¶</sup></bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âDysgeusia</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">4 (10)</td>
                        <td align="center" rowspan="1" colspan="1">4 (10)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8)</td>
                        <td align="center" rowspan="1" colspan="1">9 (23)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âAgeusia</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">âHypogeusia</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Data are presented as n or n (%). INR: international normalised ratio. <sup>#</sup>: data in this column count the patient over all treatment periods (one patient who had an AE at two or more different doses was counted only once); <sup>Â¶</sup>: data are shown only for the dose at which the event first occurred, regardless of whether the event continued or recurred at subsequent doses.</p>
                  </table-wrap-foot>
                </table-wrap>
                <p>On the cumulative assessment, the incidence of taste-related AEs was 3% for placebo, and 5%, 10%, 15% and 21% for eliapixant 10, 50, 200 and 750âmg, respectively.</p>
              </sec>
              <sec id="s3d">
                <title>Pharmacokinetics</title>
                <p>Plasma concentrations of eliapixant increased with dose in a nonlinear fashion (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04240-2020.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S4</ext-link>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>This study investigated the efficacy, safety and tolerability of the highly selective P2X3 receptor antagonist eliapixant in patients with RCC. The demographics [<xref rid="C30" ref-type="bibr">30</xref>], baseline cough frequency and LCQ score were comparable to those reported elsewhere for patients with UCC [<xref rid="C31" ref-type="bibr">31</xref>], suggesting that the study population was typical of RCC patients seen in the clinic.</p>
              <p>Eliapixant produced dose-dependent reductions in cough frequency and severity, and improvements in cough-related quality of life. The reduction in cough frequency appeared to reach a plateau at 200âmg, whereas the subjective end-points continued to improve at the 750âmg dose. While some patients had previously participated in clinical trials of gefapixant, this is unlikely to have substantially biased the results, as patients were required to have taken their last dose of prior medication at least 2âmonths before the first dose of study medication in the present study.</p>
              <p>The changes in cough frequency and severity were seen after 1âweek of each dose of eliapixant, even though the compound would have taken â¼5âdays to reach steady-state plasma levels with the applied dosing regimen (Bayer, data on file). The sparse sampling conducted in the present study meant that no pharmacokinetic parameters could be calculated using noncompartmental methods. In part 1 of the study, in healthy volunteers (to be published separately) increases in plasma concentrations with increasing eliapixant dose were less than dose proportional. Peak plasma concentrations were reached 3â4âh after administration of the first and subsequent doses, and the terminal half-life ranged from 52 to 78âh. The 200 and 750âmg doses achieve plasma drug concentrations shown to produce P2X3 receptor occupancy &gt;80% in pre-clinical and <italic toggle="yes">in vitro</italic> models: the concentration required to occupy 80% of P2X2/3 receptors is â¼20 times higher (Bayer, data on file). Pre-clinical data indicate that P2X3 receptor occupancy &gt;80% is the expected relevant threshold for efficacy (Bayer, data on file).</p>
              <p>The increases in LCQ score in the current study (1.09 and 1.53 points <italic toggle="yes">versus</italic> placebo at 200 and 750âmg, respectively) are close to the minimal clinically important difference for this measure, generally reported as 1.3 points [<xref rid="C32" ref-type="bibr">32</xref>â<xref rid="C34" ref-type="bibr">34</xref>] (although higher values have been suggested [<xref rid="C33" ref-type="bibr">33</xref>]). These results should be viewed with caution because the LCQ is a validated assessment of the impact of cough on quality of life during the preceding 14âdays rather than the 1-week duration of treatment at each dose here, which may be too short to see substantial changes in quality of life. Other studies that used the LCQ typically involved treatment durations of 1â3âmonths [<xref rid="C35" ref-type="bibr">35</xref>â<xref rid="C38" ref-type="bibr">38</xref>].</p>
              <p>In recent phase 3 trials, gefapixant 45âmg twice daily, which inhibits both P2X3 and P2X2/3 receptors, reduced awake cough frequency by 18% <italic toggle="yes">versus</italic> placebo at week 12 (COUGH-1) and by 16% <italic toggle="yes">versus</italic> placebo at week 24 (COUGH-2) [<xref rid="C23" ref-type="bibr">23</xref>]. The reductions in 24-h cough frequency <italic toggle="yes">versus</italic> placebo were 18% and 15%, respectively. These studies noted a large placebo effect, with a reduction in awake cough frequency by &gt;50%. However, in a phase 2a trial of a similar scale and design to the current study, also in patients attending specialist clinics, gefapixant reduced awake cough frequency by up to 57% <italic toggle="yes">versus</italic> baseline [<xref rid="C14" ref-type="bibr">14</xref>]. The current results with a second P2X3 receptor antagonist, shown in pre-clinical studies to be highly selective for the P2X3 receptor (see earlier), suggest that P2X3 receptor antagonism is an important mechanism for the reduction of cough frequency and severity with this class of drugs. Comparisons across clinical trials of P2X3 receptor antagonists are hampered by differences in designs, patient populations and placebo effects. The efficacy of gefapixant may partly reflect a role for P2X2/3 receptor antagonism in antitussive efficacy, but it is also possible that taste-related AEs resulting from P2X2/3 blockade led patients to expect a benefit, which added as a component to P2X3-mediated efficacy. In future, comparative studies of different P2X3 antagonists of differing receptor specificity will be required to answer this question.</p>
              <p>Dysgeusia was reported in 8â10% of patients receiving eliapixant, with no dose relationship. Importantly, all taste-related AEs were mild and no patient withdrew because of these events. The incidence of taste-related AEs was higher on the cumulative analysis, reaching 21% at the highest dose (750âmg); this may reflect accumulated events from preceding dosing periods rather than a dose relationship. Results in healthy volunteers have shown similar rates of these events with eliapixant and placebo (Bayer, data on file). Patients and healthy volunteers were advised of the possibility of taste-related AEs and this, combined with unblinding by the reduction of cough, may have influenced their perception of these events. It is difficult to say how prior participation in a P2X3 antagonist trial might have influenced reporting of AEs. While some patients might have reported taste AEs more readily because they had experienced them before, others might have been less likely to do so because they were already expecting them.</p>
              <p>In phase 3 trials, taste-related AEs, mainly dysgeusia, were reported in 11â20% of patients receiving gefapixant 15âmg twice daily and 58â69% with 45âmg twice daily [<xref rid="C23" ref-type="bibr">23</xref>]. These AEs are believed to be related to antagonism of P2X2/3 receptors on gustatory afferents [<xref rid="C39" ref-type="bibr">39</xref>] as gefapixant has little selectivity for the P2X3 receptor over the P2X2/3 receptor [<xref rid="C12" ref-type="bibr">12</xref>]. Direct comparisons are difficult, but the apparent lower incidence of taste disturbances at therapeutic doses with eliapixant than with gefapixant suggests that reduction of these effects is related to specificity for P2X3 receptors over P2X2/3 receptors [<xref rid="C40" ref-type="bibr">40</xref>]. Eliapixant has a low time to peak plasma concentration, a long terminal half-life and low fluctuation of plasma levels at steady state (Bayer, data on file). These properties may improve the efficacyâtolerability balance by maintaining therapeutic concentrations throughout the dosing period while not approaching concentrations linked to taste side-effects.</p>
              <p>Another P2X3 receptor antagonist, BLU-5937, showed promise in healthy subjects [<xref rid="C41" ref-type="bibr">41</xref>, <xref rid="C42" ref-type="bibr">42</xref>]. The phase 2 study of this compound failed to achieve the primary end-point of a reduction in awake cough frequency [<xref rid="C43" ref-type="bibr">43</xref>]; a pre-specified subgroup analysis, however, demonstrated significant cough suppression. A fourth compound, S-6000918 (sivopixant), has reported encouraging results in RCC [<xref rid="C29" ref-type="bibr">29</xref>]. Comparisons across trials are problematic because of small patient numbers, differences in designs, treatment durations and patient populations, and the widely varying placebo effects between studies.</p>
              <p>An important strength of the current study is the crossover design, in which each patient served as their own control for the objectively measured end-point. A crossover design was appropriate because RCC is a chronic, symptomatic condition and the effects of eliapixant were expected to be reversible, as observed with gefapixant [<xref rid="C14" ref-type="bibr">14</xref>]. The washout period far exceeded the half-life, reducing drug-related carryover effects. Moreover, the primary end-point was assessed based on repeated measurements <italic toggle="yes">versus</italic> baseline, which would be expected to eliminate carryover effects. Limitations included potential unblinding resulting from taste-related AEs (less than with gefapixant), the small sample size, and the limited duration of treatment and follow-up. A phase 2b trial of eliapixant has been designed to address some of these limitations.</p>
              <sec id="s4a">
                <title>Conclusions</title>
                <p>The current study verifies that P2X3 receptor antagonism is an effective therapeutic pathway for the treatment of RCC. Eliapixant at doses of 200 and 750âmg significantly reduced cough frequency and severity, and was well tolerated. The study population was typical of patients with RCC [<xref rid="C30" ref-type="bibr">30</xref>] and therefore the findings are likely to be generalisable beyond clinical trial populations. Compared with gefapixant, eliapixant produced a lower rate of taste-related AEs, likely because of its greater selectivity for the P2X3 receptor. Further studies are required, but more selective P2X3 receptor antagonists such as eliapixant may be better tolerated than less selective drugs.</p>
              </sec>
            </sec>
            <sec id="s5">
              <title>Supplementary material</title>
              <supplementary-material id="supplementary" position="float" content-type="local-data">
                <object-id pub-id-type="doi">10.1183/13993003.04240-2020.Supp1</object-id>
                <p><bold>Please note:</bold> supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.</p>
                <p>Supplementary material <inline-supplementary-material id="SS1" xlink:href="ERJ-04240-2020.SUPPLEMENT.pdf" content-type="local-data">ERJ-04240-2020.SUPPLEMENT</inline-supplementary-material></p>
              </supplementary-material>
            </sec>
            <sec id="s6">
              <title>Shareable PDF</title>
              <supplementary-material id="shareable" position="float" content-type="local-data">
                <object-id pub-id-type="doi">10.1183/13993003.04240-2020.Shareable1</object-id>
                <p>This one-page PDF can be shared freely online.</p>
                <p>Shareable PDF <inline-supplementary-material id="SS2" xlink:href="ERJ-04240-2020.Shareable.pdf" content-type="local-data">ERJ-04240-2020.Shareable</inline-supplementary-material>
</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgements</title>
              <p>L. McGarvey acknowledges the support of the Northern Ireland Clinical Research Network and the Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility in the conduct of this study. This study was supported by the National Institute for Health Research (NIHR) Manchester Clinical Research Facility.</p>
            </ack>
            <fn-group>
              <fn fn-type="supplementary-material">
                <p>This article has supplementary material available from <ext-link xlink:href="erj.ersjournals.com" ext-link-type="uri">erj.ersjournals.com</ext-link></p>
              </fn>
              <fn fn-type="other">
                <p>This study is registered at <ext-link xlink:href="https://clinicaltrials.gov/" ext-link-type="uri">ClinicalTrials.gov</ext-link> with identifier number NCT03310645. Availability of the data underlying this publication will be determined according to Bayer's commitment to the European Federation of Pharmaceutical Industries and Associations and Pharmaceutical Research and Manufacturers of America principles for responsible clinical trial data sharing, pertaining to scope, time-point and process of data access. Bayer commits to sharing upon request from qualified scientific and medical researchers patient-level clinical trial data, study-level clinical trial data and protocols from clinical trials in patients for medicines and indications approved in the USA and European Union as necessary for doing legitimate research. This commitment applies to data on new medicines and indications that have been approved by the European Union and US regulatory agencies on or after 1 January 2014. Interested researchers can use <ext-link xlink:href="https://www.clinicalstudydatarequest.com/" ext-link-type="uri">www.clinicalstudydatarequest.com</ext-link> to request access to anonymised patient-level data and supporting documents from clinical studies to do further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsor's section of the portal. Data access will be granted to anonymised patient-level data, protocols and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: A. Morice reports grants, personal fees, nonfinancial support and other from Bayer AG and Bayer US, during the course of the study; personal fees, nonfinancial support and other from Bellus Health and Merck Sharp &amp; Dohme Corp., personal fees and nonfinancial support from AstraZeneca, Chiesi Ltd and Boehringer Ingelheim, grants, personal fees, nonfinancial support and other from Sanofi, grants, personal fees and nonfinancial support from GlaxoSmithKline, Respivant Sciences, Inc. and Philips Respironics, grants, personal fees and other from NeRRe Therapeutics, grants from Menio Therapeutics, outside the submitted work.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: J.A. Smith reports grants and personal fees from Bayer AG, during the course of the study; grants and personal fees from Bellus Health, Shionogi Inc. and Merck Inc., outside the submitted work; and the VitaloJAK algorithm has been licensed by Manchester University NHS Foundation Trust and the University of Manchester to Vitalograph Ltd and Vitalograph Ireland (Ltd); Manchester University NHS Foundation Trust receives royalties which may be shared with the clinical division in which J.A. Smith works.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: L. McGarvey reports grants and personal fees from Bayer AG, during the conduct of the study; grants, personal fees and nonfinancial support from Chiesi, grants and personal fees from Merck &amp; Co., Inc. and Bellus Health, nonfinancial support from Boehringer Ingelheim, personal fees from Applied Clinical Intelligence, Shionogi Inc., GlaxoSmithKline, NeRRe Therapeutics and Nocion Therapeutics, other from AstraZeneca, outside the submitted work.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: S.S. Birring reports grants and personal fees from Merck, personal fees from Bayer, Shionogi Inc., Bellus Health, NeRRe Therapeutics, Nocion Therapeutics, Boehringer Ingelheim and GlaxoSmithKline, outside the submitted work.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: S.M. Parker reports personal fees for consultancy from Menlo and Merck, outside the submitted work.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: A. Turner has nothing to disclose.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: T. Hummel reports grants from Sony, Smell and Taste Lab, Takasago and Aspuraclip, personal fees from Frequency Therapeutics and Baiafoods, outside the submitted work.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: I. Gashaw was an employee of Bayer AG when the study was designed and conducted but is now an employee of Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Ingelheim, Germany.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: L. Fels is an employee of Bayer AG.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: S. Klein is an employee of Bayer AG.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: K. Franke is an employee of Bayer AG.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: C. Friedrich is an employee of Bayer AG.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p>Support statement: This study was funded by Bayer AG (Berlin, Germany). The study sponsor (Bayer AG) was responsible for study design, data collection, data analysis, data interpretation and study report writing. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit this paper for publication. Medical writing services provided by Richard Murphy of Adelphi Communications Ltd (Macclesfield, UK) were funded by Bayer AG in accordance with Good Publication Practice (GPP3) guidelines. J.A. Smith is funded by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre and a Wellcome Investigator Award, and is an NIHR Senior Investigator. Funding information for this article has been deposited with the <ext-link xlink:href="https://www.crossref.org/services/funder-registry/" ext-link-type="uri">Crossref Funder Registry</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="C1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chung</surname><given-names>KF</given-names></string-name>, <string-name><surname>Pavord</surname><given-names>ID</given-names></string-name></person-group>. <article-title>Prevalence, pathogenesis, and causes of chronic cough</article-title>. <source>Lancet</source><year>2008</year>; <volume>371</volume>: <fpage>1364</fpage>â<lpage>1374</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(08)60595-4</pub-id><pub-id pub-id-type="pmid">18424325</pub-id></mixed-citation>
              </ref>
              <ref id="C2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morice</surname><given-names>AH</given-names></string-name>, <string-name><surname>Millqvist</surname><given-names>E</given-names></string-name>, <string-name><surname>Bieksiene</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>ERS guidelines on the diagnosis and treatment of chronic cough in adults and children</article-title>. <source>Eur Respir J</source><year>2020</year>; <volume>55</volume>: <fpage>1901136</fpage>. doi:<pub-id pub-id-type="doi">10.1183/13993003.01136-2019</pub-id><pub-id pub-id-type="pmid">31515408</pub-id></mixed-citation>
              </ref>
              <ref id="C3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Chang</surname><given-names>YS</given-names></string-name>, <string-name><surname>Farqui</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The global epidemiology of chronic cough in adults: a systematic review and meta-analysis</article-title>. <source>Eur Respir J</source><year>2015</year>; <volume>45</volume>: <fpage>1479</fpage>â<lpage>1481</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00218714</pub-id><pub-id pub-id-type="pmid">25657027</pub-id></mixed-citation>
              </ref>
              <ref id="C4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Latti</surname><given-names>AM</given-names></string-name>, <string-name><surname>Pekkanen</surname><given-names>J</given-names></string-name>, <string-name><surname>Koskela</surname><given-names>HO</given-names></string-name></person-group>. <article-title>Persistence of chronic cough in a community-based population</article-title>. <source>ERJ Open Res</source><year>2020</year>; <volume>6</volume>: <fpage>00229-2019</fpage>. doi:<pub-id pub-id-type="doi">10.1183/23120541.00229-2019</pub-id><pub-id pub-id-type="pmid">32494575</pub-id></mixed-citation>
              </ref>
              <ref id="C5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>French</surname><given-names>CL</given-names></string-name>, <string-name><surname>Irwin</surname><given-names>RS</given-names></string-name>, <string-name><surname>Curley</surname><given-names>FJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Impact of chronic cough on quality of life</article-title>. <source>Arch Intern Med</source><year>1998</year>; <volume>158</volume>: <fpage>1657</fpage>â<lpage>1661</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinte.158.15.1657</pub-id><pub-id pub-id-type="pmid">9701100</pub-id></mixed-citation>
              </ref>
              <ref id="C6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>French</surname><given-names>CL</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>SL</given-names></string-name>, <string-name><surname>Bova</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Change in psychological, physiological, and situational factors in adults after treatment of chronic cough</article-title>. <source>Chest</source><year>2017</year>; <volume>152</volume>: <fpage>547</fpage>â<lpage>562</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chest.2017.06.024</pub-id><pub-id pub-id-type="pmid">28684289</pub-id></mixed-citation>
              </ref>
              <ref id="C7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Faruqi</surname><given-names>S</given-names></string-name>, <string-name><surname>Murdoch</surname><given-names>RD</given-names></string-name>, <string-name><surname>Allum</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><article-title>On the definition of chronic cough and current treatment pathways: an international qualitative study</article-title>. <source>Cough</source><year>2014</year>; <volume>10</volume>: <fpage>5</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1745-9974-10-5</pub-id><pub-id pub-id-type="pmid">25009577</pub-id></mixed-citation>
              </ref>
              <ref id="C8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonvini</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Belvisi</surname><given-names>MG</given-names></string-name></person-group>. <article-title>Cough and airway disease: the role of ion channels</article-title>. <source>Pulm Pharmacol Ther</source><year>2017</year>; <volume>47</volume>: <fpage>21</fpage>â<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pupt.2017.06.009</pub-id><pub-id pub-id-type="pmid">28669932</pub-id></mixed-citation>
              </ref>
              <ref id="C9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Morice</surname><given-names>AH</given-names></string-name></person-group>. <article-title>Cough hypersensitivity syndrome: a few more steps forward</article-title>. <source>Allergy Asthma Immunol Res</source><year>2017</year>; <volume>9</volume>: <fpage>394</fpage>â<lpage>402</lpage>. doi:<pub-id pub-id-type="doi">10.4168/aair.2017.9.5.394</pub-id><pub-id pub-id-type="pmid">28677352</pub-id></mixed-citation>
              </ref>
              <ref id="C10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morice</surname><given-names>AH</given-names></string-name>, <string-name><surname>Kitt</surname><given-names>MM</given-names></string-name>, <string-name><surname>Ford</surname><given-names>AP</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study</article-title>. <source>Eur Respir J</source><year>2019</year>; <volume>54</volume>: <fpage>1900439</fpage>. doi:<pub-id pub-id-type="doi">10.1183/13993003.00439-2019</pub-id><pub-id pub-id-type="pmid">31023843</pub-id></mixed-citation>
              </ref>
              <ref id="C11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muccino</surname><given-names>D</given-names></string-name>, <string-name><surname>Green</surname><given-names>S</given-names></string-name></person-group>. <article-title>Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough</article-title>. <source>Pulm Pharmacol Ther</source><year>2019</year>; <volume>56</volume>: <fpage>75</fpage>â<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pupt.2019.03.006</pub-id><pub-id pub-id-type="pmid">30880151</pub-id></mixed-citation>
              </ref>
              <ref id="C12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname><given-names>D</given-names></string-name>, <string-name><surname>Gever</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ford</surname><given-names>AP</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and <italic toggle="yes">in vivo</italic> efficacy in models of sensitisation</article-title>. <source>Br J Pharmacol</source><year>2019</year>; <volume>176</volume>: <fpage>2279</fpage>â<lpage>2291</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bph.14677</pub-id><pub-id pub-id-type="pmid">30927255</pub-id></mixed-citation>
              </ref>
              <ref id="C13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>JA</given-names></string-name>, <string-name><surname>Kitt</surname><given-names>MM</given-names></string-name>, <string-name><surname>Butera</surname><given-names>P</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Gefapixant in two randomised dose-escalation studies in chronic cough</article-title>. <source>Eur Respir J</source><year>2020</year>; <volume>55</volume>: <fpage>1901615</fpage>. doi:<pub-id pub-id-type="doi">10.1183/13993003.01615-2019</pub-id><pub-id pub-id-type="pmid">31949115</pub-id></mixed-citation>
              </ref>
              <ref id="C14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>JA</given-names></string-name>, <string-name><surname>Kitt</surname><given-names>MM</given-names></string-name>, <string-name><surname>Morice</surname><given-names>AH</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial</article-title>. <source>Lancet Respir Med</source><year>2020</year>; <volume>8</volume>: <fpage>P775</fpage>â<lpage>P785</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(19)30471-0</pub-id></mixed-citation>
              </ref>
              <ref id="C15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burnstock</surname><given-names>G</given-names></string-name></person-group>. <article-title>Purinergic signalling: from discovery to current developments</article-title>. <source>Exp Physiol</source><year>2014</year>; <volume>99</volume>: <fpage>16</fpage>â<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.1113/expphysiol.2013.071951</pub-id><pub-id pub-id-type="pmid">24078669</pub-id></mixed-citation>
              </ref>
              <ref id="C16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burnstock</surname><given-names>G</given-names></string-name></person-group>. <article-title>Purine and purinergic receptors</article-title>. <source>Brain Neurosci Adv</source><year>2018</year>; <volume>2</volume>: <fpage>2398212818817494</fpage>. doi:<pub-id pub-id-type="doi">10.1177/2398212818817494</pub-id><pub-id pub-id-type="pmid">32166165</pub-id></mixed-citation>
              </ref>
              <ref id="C17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>North</surname><given-names>RA</given-names></string-name></person-group>. <article-title>P2X receptors</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source><year>2016</year>; <volume>371</volume>: <fpage>20150427</fpage>. doi:<pub-id pub-id-type="doi">10.1098/rstb.2015.0427</pub-id><pub-id pub-id-type="pmid">27377721</pub-id></mixed-citation>
              </ref>
              <ref id="C18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>North</surname><given-names>RA</given-names></string-name>, <string-name><surname>Surprenant</surname><given-names>A</given-names></string-name></person-group>. <article-title>Pharmacology of cloned P2X receptors</article-title>. <source>Annu Rev Pharmacol Toxicol</source><year>2000</year>; <volume>40</volume>: <fpage>563</fpage>â<lpage>580</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.pharmtox.40.1.563</pub-id><pub-id pub-id-type="pmid">10836147</pub-id></mixed-citation>
              </ref>
              <ref id="C19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kwong</surname><given-names>K</given-names></string-name>, <string-name><surname>Kollarik</surname><given-names>M</given-names></string-name>, <string-name><surname>Nassenstein</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>P2X2 receptors differentiate placodal <italic toggle="yes">vs.</italic> neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source><year>2008</year>; <volume>295</volume>: <fpage>L858</fpage>â<lpage>L865</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajplung.90360.2008</pub-id><pub-id pub-id-type="pmid">18689601</pub-id></mixed-citation>
              </ref>
              <ref id="C20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryan</surname><given-names>NM</given-names></string-name>, <string-name><surname>Vertigan</surname><given-names>AE</given-names></string-name>, <string-name><surname>Birring</surname><given-names>SS</given-names></string-name></person-group>. <article-title>An update and systematic review on drug therapies for the treatment of refractory chronic cough</article-title>. <source>Expert Opin Pharmacother</source><year>2018</year>; <volume>19</volume>: <fpage>687</fpage>â<lpage>711</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14656566.2018.1462795</pub-id><pub-id pub-id-type="pmid">29658795</pub-id></mixed-citation>
              </ref>
              <ref id="C21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Satia</surname><given-names>I</given-names></string-name>, <string-name><surname>Badri</surname><given-names>H</given-names></string-name>, <string-name><surname>Al-Sheklly</surname><given-names>B</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Towards understanding and managing chronic cough</article-title>. <source>Clin Med</source><year>2016</year>; <volume>16</volume>: <issue>Suppl. 6</issue>, <fpage>S92</fpage>â<lpage>S97</lpage>. doi:<pub-id pub-id-type="doi">10.7861/clinmedicine.16-6-s92</pub-id></mixed-citation>
              </ref>
              <ref id="C22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shapiro</surname><given-names>CO</given-names></string-name>, <string-name><surname>Proskocil</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Oppegard</surname><given-names>LJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Airway sensory nerve density is increased in chronic cough</article-title>. <source>Am J Respir Crit Care Med</source><year>2021</year>; <volume>203</volume>: <fpage>348</fpage>â<lpage>355</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201912-2347OC</pub-id><pub-id pub-id-type="pmid">32809840</pub-id></mixed-citation>
              </ref>
              <ref id="C23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGarvey</surname><given-names>L</given-names></string-name>, <string-name><surname>Birring</surname><given-names>SS</given-names></string-name>, <string-name><surname>Morice</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Two phase 3 randomized clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (COUGH-1 and COUGH-2)</article-title>. <source>Eur Respir J</source><year>2020</year>; <volume>56</volume>: <issue>Suppl. 64</issue>, <fpage>3800</fpage>. doi:<pub-id pub-id-type="doi">10.1183/13993003.congress-2020.3800</pub-id></mixed-citation>
              </ref>
              <ref id="C24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdulqawi</surname><given-names>R</given-names></string-name>, <string-name><surname>Dockry</surname><given-names>R</given-names></string-name>, <string-name><surname>Holt</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study</article-title>. <source>Lancet</source><year>2015</year>; <volume>385</volume>: <fpage>1198</fpage>â<lpage>1205</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(14)61255-1</pub-id><pub-id pub-id-type="pmid">25467586</pub-id></mixed-citation>
              </ref>
              <ref id="C25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morice</surname><given-names>AH</given-names></string-name>, <string-name><surname>McGarvey</surname><given-names>L</given-names></string-name>, <string-name><surname>Pavord</surname><given-names>I</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Recommendations for the management of cough in adults</article-title>. <source>Thorax</source><year>2006</year>; <volume>61</volume>: Suppl. 1, <fpage>i1</fpage>â<lpage>i24</lpage>. doi:<pub-id pub-id-type="doi">10.1136/thx.2006.065144</pub-id><pub-id pub-id-type="pmid">16936230</pub-id></mixed-citation>
              </ref>
              <ref id="C26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fark</surname><given-names>T</given-names></string-name>, <string-name><surname>Hummel</surname><given-names>C</given-names></string-name>, <string-name><surname>HÃ¤hner</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Characteristics of taste disorders</article-title>. <source>Eur Arch Otorhinolaryngol</source><year>2013</year>; <volume>270</volume>: <fpage>1855</fpage>â<lpage>1860</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00405-012-2310-2</pub-id><pub-id pub-id-type="pmid">23229645</pub-id></mixed-citation>
              </ref>
              <ref id="C27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdulqawi</surname><given-names>R</given-names></string-name>, <string-name><surname>Woodcock</surname><given-names>A</given-names></string-name>, <string-name><surname>Smith</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Gabapentin for refractory chronic cough</article-title>. <source>Lancet</source><year>2013</year>; <volume>381</volume>: <fpage>623</fpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(13)60337-2</pub-id></mixed-citation>
              </ref>
              <ref id="C28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGuinness</surname><given-names>K</given-names></string-name>, <string-name><surname>Holt</surname><given-names>K</given-names></string-name>, <string-name><surname>Dockry</surname><given-names>R</given-names></string-name>, <etal>et al.</etal></person-group><article-title>P159 Validation of the VitaloJAK 24âhour ambulatory cough monitor</article-title>. <source>Thorax</source><year>2012</year>; <volume>67</volume>: <issue>Suppl. 2</issue>, <fpage>A131</fpage>. doi:<pub-id pub-id-type="doi">10.1136/thoraxjnl-2012-202678.220</pub-id></mixed-citation>
              </ref>
              <ref id="C29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niimi</surname><given-names>A</given-names></string-name>, <string-name><surname>Ishihara</surname><given-names>H</given-names></string-name>, <string-name><surname>Hida</surname><given-names>H</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough</article-title>. <source>Eur Respir J</source><year>2019</year>; <volume>54</volume>: <issue>Suppl. 63</issue>, <fpage>RCT452</fpage>. doi:<pub-id pub-id-type="doi">10.1183/13993003.congress-2019.RCT452</pub-id></mixed-citation>
              </ref>
              <ref id="C30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morice</surname><given-names>AH</given-names></string-name>, <string-name><surname>Jakes</surname><given-names>AD</given-names></string-name>, <string-name><surname>Faruqi</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response</article-title>. <source>Eur Respir J</source><year>2014</year>; <volume>44</volume>: <fpage>1149</fpage>â<lpage>1155</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00217813</pub-id><pub-id pub-id-type="pmid">25186267</pub-id></mixed-citation>
              </ref>
              <ref id="C31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yousaf</surname><given-names>N</given-names></string-name>, <string-name><surname>Monteiro</surname><given-names>W</given-names></string-name>, <string-name><surname>Matos</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cough frequency in health and disease</article-title>. <source>Eur Respir J</source><year>2013</year>; <volume>41</volume>: <fpage>241</fpage>â<lpage>243</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00089312</pub-id><pub-id pub-id-type="pmid">23277523</pub-id></mixed-citation>
              </ref>
              <ref id="C32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raj</surname><given-names>AA</given-names></string-name>, <string-name><surname>Pavord</surname><given-names>DI</given-names></string-name>, <string-name><surname>Birring</surname><given-names>SS</given-names></string-name></person-group>. <article-title>Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire?</article-title><source>Handb Exp Pharmacol</source><year>2009</year>; <volume>187</volume>: <fpage>311</fpage>â<lpage>320</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-3-540-79842-2_16</pub-id></mixed-citation>
              </ref>
              <ref id="C33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rebelo</surname><given-names>P</given-names></string-name>, <string-name><surname>Oliveira</surname><given-names>A</given-names></string-name>, <string-name><surname>Paixao</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Minimal clinically important differences for patient-reported outcome measures of cough and sputum in patients with COPD</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source><year>2020</year>; <volume>15</volume>: <fpage>201</fpage>â<lpage>212</lpage>. doi:<pub-id pub-id-type="doi">10.2147/COPD.S219480</pub-id><pub-id pub-id-type="pmid">32099345</pub-id></mixed-citation>
              </ref>
              <ref id="C34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spinou</surname><given-names>A</given-names></string-name>, <string-name><surname>Birring</surname><given-names>SS</given-names></string-name></person-group>. <article-title>An update on measurement and monitoring of cough: what are the important study endpoints?</article-title><source>J Thorac Dis</source><year>2014</year>; <volume>6</volume>: <issue>Suppl. 7</issue>, <fpage>S728</fpage>â<lpage>S734</lpage>. doi:<pub-id pub-id-type="doi">10.3978/j.issn.2072-1439.2014.10.08</pub-id><pub-id pub-id-type="pmid">25383207</pub-id></mixed-citation>
              </ref>
              <ref id="C35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morice</surname><given-names>AH</given-names></string-name>, <string-name><surname>Menon</surname><given-names>MS</given-names></string-name>, <string-name><surname>Mulrennan</surname><given-names>SA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Opiate therapy in chronic cough</article-title>. <source>Am J Respir Crit Care Med</source><year>2007</year>; <volume>175</volume>: <fpage>312</fpage>â<lpage>315</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.200607-892OC</pub-id><pub-id pub-id-type="pmid">17122382</pub-id></mixed-citation>
              </ref>
              <ref id="C36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yousaf</surname><given-names>N</given-names></string-name>, <string-name><surname>Monteiro</surname><given-names>W</given-names></string-name>, <string-name><surname>Parker</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial</article-title>. <source>Thorax</source><year>2010</year>; <volume>65</volume>: <fpage>1107</fpage>â<lpage>1110</lpage>. doi:<pub-id pub-id-type="doi">10.1136/thx.2010.142711</pub-id><pub-id pub-id-type="pmid">20965928</pub-id></mixed-citation>
              </ref>
              <ref id="C37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryan</surname><given-names>NM</given-names></string-name>, <string-name><surname>Birring</surname><given-names>SS</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>PG</given-names></string-name></person-group>. <article-title>Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source><year>2012</year>; <volume>380</volume>: <fpage>1583</fpage>â<lpage>1589</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(12)60776-4</pub-id><pub-id pub-id-type="pmid">22951084</pub-id></mixed-citation>
              </ref>
              <ref id="C38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vertigan</surname><given-names>AE</given-names></string-name>, <string-name><surname>Kapela</surname><given-names>SL</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>NM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial</article-title>. <source>Chest</source><year>2016</year>; <volume>149</volume>: <fpage>639</fpage>â<lpage>648</lpage>. doi:<pub-id pub-id-type="doi">10.1378/chest.15-1271</pub-id><pub-id pub-id-type="pmid">26447687</pub-id></mixed-citation>
              </ref>
              <ref id="C39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garceau</surname><given-names>D</given-names></string-name>, <string-name><surname>Chauret</surname><given-names>N</given-names></string-name></person-group>. <article-title>BLU-5937: a selective P2X3 antagonist with potent anti-tussive effect and no taste alteration</article-title>. <source>Pulm Pharmacol Ther</source><year>2019</year>; <volume>56</volume>: <fpage>56</fpage>â<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pupt.2019.03.007</pub-id><pub-id pub-id-type="pmid">30902655</pub-id></mixed-citation>
              </ref>
              <ref id="C40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morice</surname><given-names>A</given-names></string-name></person-group>. <article-title>ATP cough challenge</article-title>. <source>Pulm Pharmacol Ther</source><year>2019</year>; <volume>58</volume>: <fpage>101835</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pupt.2019.101835</pub-id><pub-id pub-id-type="pmid">31437483</pub-id></mixed-citation>
              </ref>
              <ref id="C41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garceau</surname><given-names>D</given-names></string-name>, <string-name><surname>Chauret</surname><given-names>N</given-names></string-name>, <string-name><surname>Harvey</surname><given-names>L</given-names></string-name></person-group>. <article-title>BLU-5937 a highly selective P2X3 homotrimeric receptor antagonist with improved taste safety profile in healthy subjects</article-title>. <source>Am J Respir Crit Care Med</source><year>2019</year>; <volume>199</volume>: <fpage>A7396</fpage>. doi:<pub-id pub-id-type="doi">10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A7396</pub-id></mixed-citation>
              </ref>
              <ref id="C42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garceau</surname><given-names>D</given-names></string-name>, <string-name><surname>Chauret</surname><given-names>N</given-names></string-name>, <string-name><surname>Harvey</surname><given-names>L</given-names></string-name></person-group>. <article-title>BLU-5937: a highly selective P2X3 homotrimeric receptor antagonist exhibits excellent pharmacokinetic and safety profile including improved taste safety profile in healthy subjects</article-title>. <source>Lung</source><year>2020</year>; <volume>198</volume>: <fpage>38</fpage>â<lpage>39</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00408-020-00328-3</pub-id></mixed-citation>
              </ref>
              <ref id="C43">
                <label>43</label>
                <mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>Bellus Health</collab></person-group>. <comment>BELLUS Health announces topline results from its phase 2 RELIEF Trial of BLU-5937 for the treatment of refractory chronic cough</comment>. <year>2020</year>. <ext-link xlink:href="www.businesswire.com/news/home/20200706005125/en" ext-link-type="uri">www.businesswire.com/news/home/20200706005125/en</ext-link><comment>Date last accessed: 16 November 2020</comment>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
